Genomics is Key
The past decade has seen genetically targeted therapies go from theory to practice, particularly in the field of oncology. Every new disease-causing gene discovered opens up a new line of attack on rare, intractable, and chronic diseases, but health systems risk multiple bottlenecks that might derail progress. While there are ethical, logistical, and scientific challenges to overcome, what might the potential opportunity be for genetically-characterised populations to accelerate research and care?
FACILITATED BY
PATRICK SHORTÂ | Co-founder and Chief Executive Officer | Sano Genetics
PANELLISTS INCLUDE
ANDREW RODDAM | Chief Executive Officer | Our Future Health
JOANNE HACKETT | Head of Genomic and Precision Medicine | IQVIA
DIRK PAUL | Senior Director, CVRM Genomics | AstraZeneca
JAMES DUBOFF | Strategic Partnerships Director | Genomics England